Fuente y mas informacion:
jueves, 23 octubre, 2008
De: "MMRF SmartBrief "
http://www.multiplemyeloma.org/

Expert Rev Anticancer Ther. 2008 Oct
Role of thalidomide in previously untreated patients with multiple myeloma
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Musto P, D'Auria F, Pietrantuono G, Bringhen S, Morabito F, Di Raimondo F, Pozzi S, Sacchi S, Boccadoro M, Palumbo A; Gruppo Italiano Malatte Ematologiche dell'Adulto Multiple Myeloma Working Party; Italian Myeloma Network and Gruppo Italiano Studio Linfomi


Oncologist. 2008 Oct 15
Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Hazarika M, Rock E, Williams G, Dagher R, Sridhara R, Booth B, Farrell A, Justice R, Pazdur R


Clin Lymphoma Myeloma. 2008 Oct
Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Fonseca R, Rajkumar SV


Intensive Care Med. 2008 Oct 14
Continued survival gains in recent years among critically ill myeloma patients
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Peigne V, Rusinov? K, Karlin L, Darmon M, Fermand JP, Schlemmer B, Azoulay E





____________
Un saludo
Victor Quesada
Webmaster y Administrador de Mieloma.com

Guia de Uso - http://www.mieloma.com/ayuda/

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Fuente y mas informacion:
Myeloma Minute - October 22, 2008
http://readtheminute.myeloma.org/

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
David C Johnson*, Sophie Corthals, Christine Ramos, Antje Hoering, Kim Cocks, Nicholas J Dickens, Jeff Haessler, Harmut Goldschmidt*, J. Anthony Child*, Sue E Bell, Graham Jackson, Dalsu Baris*, S. Vincent Rajkumar*, Faith E Davies*, Brian G.M. Durie*, John Crowley*, Pieter Sonneveld*, Brian Van Ness*, and Gareth J Morgan*
Blood published 19 September 2008, 10.1182/blood-2008-02-140434
http://bloodjournal.hematologylibra...40434v1?papetoc

Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator
Yan Jiao, John Wilkinson, IV, Xiumin Di, Wei Wang, Heather Hatcher, Nancy D. Kock, Ralph D'Agostino, Jr., Mary Ann Knovich, Frank M. Torti, and Suzy V. Torti
Blood published 24 September 2008, 10.1182/blood-2008-05-155952
http://bloodjournal.hematologylibra...55952v1?papetoc

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3
Erik A Nelson, Sarah R Walker, Alicia Kepich, Laurie B Gashin, Teru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, Kenneth C. Anderson*, and David A Frank
Blood published 29 September 2008, 10.1182/blood-2007-12-129718
http://bloodjournal.hematologylibra...29718v1?papetoc


The role of Dickkopf-1 in bone development, homeostasis and disease
Joseph J. Pinzone, Brett M. Hall, Nanda K. Thudi, Martin Vonau, Ya-Wei Qiang, Thomas J. Rosol, and John D. Shaughnessy Jr.
Blood published 3 October 2008, 10.1182/blood-2008-03-145169
http://bloodjournal.hematologylibra...45169v2?papetoc

Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors
Masako Iwanaga, Masuko Tagawa, Kunihiro Tsukasaki, Tatsuki Matsuo, Ken-ichi Yokota, Yasushi Miyazaki, Takuya Fukushima, Tomoko Hata, Yoshitaka Imaizumi, Daisuke Imanishi, Jun Taguchi, Sabro Momita, Shimeru Kamihira, and Masao Tomonaga
Blood published 10 October 2008, 10.1182/blood-2008-05-159665
http://bloodjournal.hematologylibra...59665v1?papetoc

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
Antonio Palumbo*, Sara Bringhen, Anna M. Liberati, Tommaso Caravita, Antonietta Falcone, Vincenzo Callea, Marco Montanaro, Roberto Ria, Antonio Capaldi, Renato Zambello, Giulia Benevolo, Daniele Derudas, Fausto Dore, Federica Cavallo, Francesca Gay, Patrizia Falco, Giovannino Ciccone, Pellegrino Musto, Michele Cavo, and Mario Boccadoro*
Blood 2008; 15 October 2008, Vol 112 3107-3114
http://bloodjournal.hematologylibra...112/8/3107?etoc

Crossover confusion: MPT still best
Brian G. M. Durie*
A comment by Dr. Durie on the article above.
http://bloodjournal.hematologylibra...full/112/8/2998

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma
Angela Zollinger, Thorsten Stuhmer, Manik Chatterjee, Stefan Gattenlohner, Eugenia Haralambieva, Hans-Konrad Muller-Hermelink, Mindaugas Andrulis, Axel Greiner, Carmen Wesemeier, Jorg C. Rath, Hermann Einsele*, and Ralf C. Bargou
Blood 2008; 15 October 2008, Vol 112 3403-3411
http://bloodjournal.hematologylibra...112/8/3403?etoc


Need akt? Some myelomas do
P. Leif Bergsagel*
Blood 2008;15 October 2008, Vol 112 3004-3005
http://bloodjournal.hematologylibra...112/8/3004?etoc

A Comment by Dr. Bergsagel on the article above.


Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Bart Barlogie*, Frits van Rhee, John D. Shaughnessy, Jr, Joshua Epstein, Shmuel Yaccoby, Mauricio Pineda-Roman, Klaus Hollmig, Yazan Alsayed, Antje Hoering, Jackie Szymonifka, Elias Anaissie, Nathan Petty, Naveen S. Kumar, Geetika Srivastava, Bonnie Jenkins, John Crowley*, and Jerome B. Zeldis
Blood 2008;112 3122-3125
http://bloodjournal.hematologylibra...112/8/3122?etoc

Biology, treatment, and time
Angela Dispenzieri
Blood, 15 October 2008, Vol. 112, No. 8, pp. 2999-3000
http://bloodjournal.hematologylibra...full/112/8/2999

A comment by Dr. Dispenzieri on the article above.


Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
Bart Barlogie*, Mauricio Pineda-Roman, Frits van Rhee, Jeff Haessler, Elias Anaissie, Klaus Hollmig, Yazan Alsayed, Sarah Waheed, Nathan Petty, Joshua Epstein, John D. Shaughnessy, Jr, Guido Tricot*, Maurizio Zangari, Jerome Zeldis, Sol Barer, and John Crowley*
Blood 2008; 15 October 2008, Vol 112 3115-3121
http://bloodjournal.hematologylibra...112/8/3115?etoc

Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma
Oliver C. Goodyear, Guy Pratt, Andrew McLarnon, Mark Cook, Karen Piper, and Paul Moss
Blood 2008;112 3362-3372
http://bloodjournal.hematologylibra...112/8/3362?etoc

Current status of autologous hematopoietic stem cell transplantation in myeloma.
Mehta J*, Singhal S*.
Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S28-S34
http://www.ncbi.nlm.nih.gov/pubmed/18724294





____________
Un saludo
Victor Quesada
Webmaster y Administrador de Mieloma.com

Guia de Uso - http://www.mieloma.com/ayuda/

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Fuente y mas informacion:
jueves, 16 octubre, 2008
De: "MMRF SmartBrief "
http://www.multiplemyeloma.org/

Curr Opin Oncol. 2008 Nov
Advances in therapy of multiple myeloma
Blad? J, Rosi?ol L
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum

Leukemia. 2008 Oct 9
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar K, Chauhan D, Anderson KC
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum

Bone Marrow Transplant. 2008 Oct 13
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma
Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE, Siegel DL, Cook RJ, Mangan PA, Cunningham K, Stadtmauer EA
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum

Int J Hematol. 2008 Oct 11
Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis
Hillengass J, Ho AD, Goldschmidt H, Waldherr R, Moehler TM
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum





____________
Un saludo
Victor Quesada
Webmaster y Administrador de Mieloma.com

Guia de Uso - http://www.mieloma.com/ayuda/

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.

Fuente y mas informacion:
jueves, 30 octubre, 2008
De: "MMRF SmartBrief "
http://www.multiplemyeloma.org/

Blood. 2008 Oct 27
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma
Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, Egyed M, Spicka I, Gisslinger H, Greil R, Kuhn I, Zojer N, Hinke A


Blood. 2008 Oct 23
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematological tumors by abrogating signaling via Akt and ERK
Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC


Ann Hematol. 2008 Oct 22
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Comparison of whole-body MR imaging and conventional X-ray examination in patients with multiple myeloma and implications for therapy
Dinter DJ, Neff WK, Klaus J, B?hm C, Hastka J, Weiss C, Schoenberg SO, Metzgeroth G


Bone. 2008 Oct 7
http://www.ncbi.nlm.nih.gov/pubmed/...Pubmed_RVDocSum
Osteonecrosis of the jaw -- Who gets it, and why?
Reid IR





____________
Un saludo
Victor Quesada
Webmaster y Administrador de Mieloma.com

Guia de Uso - http://www.mieloma.com/ayuda/

Ser feliz no significa que todo sea perfecto, quiere decir que has decidido seguir adelante pese a las dificultades.